Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.49 |
| ▸ | JAK3 | P52333 | 14/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966 | 0.92 | JAK2 (0.57) | JAK2JAK3PTK2 | |
| SCHEMBL15207388 | 0.86 | JAK2 (0.45) | JAK2JAK3PTK2PIK3CGPIK3CB | |
| SCHEMBL20987 | 0.84 | JAK2 (0.47) | JAK2JAK3PTK2PIK3CG | |
| SCHEMBL15207613 | 0.84 | JAK2 (0.43) | JAK2JAK3PTK2PIK3CG | |
| SCHEMBL15207245 | 0.84 | JAK2 (0.41) | JAK2JAK3PTK2ZAP70 | |
| SCHEMBL20933 | 0.84 | JAK2 (0.48) | JAK2JAK3PTK2PIK3CGPIK3CB | |
| SCHEMBL19512 | 0.83 | JAK2 (0.45) | JAK2JAK3PTK2PIK3CGPIK3CB | |
| SCHEMBL15207402 | 0.83 | JAK2 (0.45) | JAK2JAK3PTK2PIK3CGPIK3CB | |
| SCHEMBL21584 | 0.82 | FLT1 (0.44) | JAK2JAK3PTK2ZAP70KARS1 | |
| SCHEMBL20859 | 0.82 | JAK2 (0.48) | JAK2JAK3PTK2ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | JAK2 5/4885JAK3 32/4885PTK2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.